- Home
- PLX vs CABA Comparison
PLX vs CABA Comparison
Compare PLX & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- CABA
- Stock Information
- Founded
- PLX 1993
- CABA 2017
- Country
- PLX United States
- CABA United States
- Employees
- PLX N/A
- CABA N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- CABA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PLX Health Care
- CABA Health Care
- Exchange
- PLX Nasdaq
- CABA Nasdaq
- Market Cap
- PLX 204.9M
- CABA 200.3M
- IPO Year
- PLX 1998
- CABA 2019
- Fundamental
- Price
- PLX $1.85
- CABA $2.85
- Analyst Decision
- PLX Strong Buy
- CABA Strong Buy
- Analyst Count
- PLX 1
- CABA 8
- Target Price
- PLX $15.00
- CABA $11.63
- AVG Volume (30 Days)
- PLX 1.1M
- CABA 5.1M
- Earning Date
- PLX 11-13-2025
- CABA 11-13-2025
- Dividend Yield
- PLX N/A
- CABA N/A
- EPS Growth
- PLX N/A
- CABA N/A
- EPS
- PLX 0.08
- CABA N/A
- Revenue
- PLX $61,948,000.00
- CABA N/A
- Revenue This Year
- PLX $14.53
- CABA N/A
- Revenue Next Year
- PLX $75.77
- CABA N/A
- P/E Ratio
- PLX $24.02
- CABA N/A
- Revenue Growth
- PLX 62.79
- CABA N/A
- 52 Week Low
- PLX $1.01
- CABA $0.99
- 52 Week High
- PLX $3.10
- CABA $5.46
- Technical
- Relative Strength Index (RSI)
- PLX 38.39
- CABA 60.41
- Support Level
- PLX $2.31
- CABA $2.23
- Resistance Level
- PLX $2.55
- CABA $3.08
- Average True Range (ATR)
- PLX 0.15
- CABA 0.34
- MACD
- PLX -0.06
- CABA 0.02
- Stochastic Oscillator
- PLX 23.70
- CABA 50.45
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About CABA Cabaletta Bio Inc.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.